CU-CPT-9b (TLR8-specific antagonist 1) |
カタログ番号GC31729 |
CU-CPT-9b (TLR8 特異的拮抗薬 1) は特異的な TLR8 拮抗薬であり、IC50 は 0.7 nM です。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2162962-69-6
Sample solution is provided at 25 µL, 10mM.
CU-CPT-9b is a specific TLR8 antagonist, with an IC50 of 0.7 nM.
CU-CPT-9b is a specific TLR8 antagonist, with an IC50 of 0.7±0.2 nM. ITC experiments have confirmed the strong binding of CU-CPT-9b with a Kd of 21 nM. It is shown that CU-CPT-9b binds to the inactive TLR8 dimer in a similar way to CU-CPT8m. CU-CPT9b utilizes hydrogen bonds with G351 and V520*, which are conserved among TLR8/antagonist structures. Additionally, CU-CPT-9b forms water-mediated contacts with S516* and Q519*, which are not observed in TLR8/CU-CPT8m structure, suggesting that the enhanced potency of CU-CPT-9b derives from the new interactions with these polar residues. The orientation of Y567* also changes to facilitate van der Waals interactions with CU-CPT-9b as compared to TLR8/CU-CPT8m[1].
[1]. Zhang S, et al. Small-molecule inhibition of TLR8 through stabilization of its resting state. Nat Chem Biol. 2018 Jan;14(1):58-64.
Average Rating: 5
(Based on Reviews and 14 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *